An adjuvant is a vaccine component that boosts the immune response to the vaccine. An adjuvant is used to create a stronger immune response in people receiving the vaccine. In short, adjuvants help vaccines work better. Newer adjuvants have been developed to target specific components of the body’s immune response, so that protection against disease is stronger and lasts longer.
Rise in prevalence of chronic/infectious diseases, increasing use of vaccine adjuvants, government initiatives or policies for immunization, outbreak of COVID-19 (pandemic), and increase in focus on the development of safe and effective vaccine are major factors expected to drive growth of the global vaccine adjuvants market over the forecast period.
For instance, in October 2022, MHRP and collaborators recently launched a Phase 1 trial that will evaluate safety, tolerability, and immunogenicity of varying doses of the Army’s ALFQ adjuvant in a candidate HIV vaccine to optimize adjuvant dosage.
Furthermore, in August 2021, Medigen Vaccine Biologics Corporation and Dynavax Technologies Corporation announced the rollout of its COVID-19 vaccine, MVC-COV1901. More than 600,000 people are anticipated to receive the Medigen vaccine this week.
- This report provides in-depth analysis of the global vaccine adjuvants market, and provides market size (USD Mn) and compound annual growth rate (CAGR %) for the forecast period (2026–2033), considering 2025 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global vaccine adjuvants market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Air Liquide (Seppic), Pacific GeneTech Limited, OZ Biosciences, Novavax Inc., Merck & Co. Inc., InvivoGen, GlaxoSmithKline PLC, Dynavax Technologies Corporation, CSL Limited, Croda International PLC, Vertellus, Aphios Corporation, Agenus Inc., Adjuvatis, and Associated British Foods PLC (SPI Pharma Inc.)
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global vaccine adjuvants market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global vaccine adjuvants market.
-
- Mineral Salt-based Adjuvant
- Tensoactive Adjuvants
- Adjuvant Emulsions
- Liposome Adjuvants
- Carbohydrate Adjuvants
- Bacteria-derived Adjuvants
- Virus-like Particles (VLP)
- Other Types
-
- Active Immunostimulants
- Carriers
-
- Infectious Disease
- Cancer
-
- Research Applications
- Commercial Applications
-
- North America
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
-
- Thermo Fisher Scientific Inc.
- Air Liquide (Seppic)
- Pacific GeneTech Limited
- OZ Biosciences, Novavax Inc.
- Merck & Co. Inc.
- InvivoGen
- GlaxoSmithKline PLC
- Dynavax Technologies Corporation
- CSL Limited
- Croda International PLC
- Vertellus
- Aphios Corporation
- Agenus Inc.
- Adjuvatis
- Associated British Foods PLC (SPI Pharma Inc.)
